Zobrazeno 1 - 10
of 3 346
pro vyhledávání: '"Metastatic Renal Cell Carcinoma"'
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Introduction The majority of metastatic renal cell carcinoma (mRCC) patients receive one or more VEGFR TKI agents, alone or in combination with an immune-oncology (IO) agent or an mTOR inhibitor. To date, the cost of adverse events (AEs) com
Externí odkaz:
https://doaj.org/article/8ef7bbd24a304d5b9b93e0aceb84d027
Autor:
Goranit Sakunchotpanit, BS, Thomas Z. Rohan, BS, Jakob Moran, MD, Eleanor Russell-Goldman, MD, PhD, Michelle Walters, MD, Vinod E. Nambudiri, MD, MBA, EdM
Publikováno v:
JAAD Case Reports, Vol 52, Iss , Pp 60-62 (2024)
Externí odkaz:
https://doaj.org/article/949b5e5ec5f14039bc3380ce4c6ad788
Publikováno v:
Южно-Российский онкологический журнал, Vol 5, Iss 3, Pp 31-38 (2024)
Purpose of the study. To determine the influence of prognostic factors on survival rates in patients with metastatic renal cell carcinoma (mRCC) aged ≥ 75 years.Materials and methods. A retrospective study included 77 mRCC patients aged ≥ 75 year
Externí odkaz:
https://doaj.org/article/4045e209c99d4b8299f3281263e3be85
Autor:
Ella Xiaoyan Du, Keith A. Betts, Travis Wang, Sophie A. Kitchen, Xuanhao He, Xin Yin, Sarah B. Guttenplan, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt
Publikováno v:
Oncology and Therapy, Vol 12, Iss 4, Pp 735-751 (2024)
Abstract Introduction Nivolumab plus ipilimumab (NIVO + IPI) and pembrolizumab plus axitinib (PEM + AXI) are first-line (1L) treatments for advanced or metastatic renal cell carcinoma (aRCC), although the long-term trends in their associated real-wor
Externí odkaz:
https://doaj.org/article/e25d2e0194f14761b52eaa0aaa368dff
Autor:
Sara Elena Rebuzzi, Giuseppe Fornarini, Alessio Signori, Sebastiano Buti, Giuseppe Procopio, Ugo De Giorgi, Sandro Pignata, Emanuele Naglieri, Marco Maruzzo, Giuseppe Luigi Banna, Pasquale Rescigno, Carlo Messina, Alvise Mattana, Umberto Basso, Davide Bimbatti
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-5 (2024)
Abstract Background Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the standard first-line therapy in all mRCC patients regardless of the Internati
Externí odkaz:
https://doaj.org/article/07fb9d1891ed48f8877a4dc092e2bedf
Autor:
Margaret F. Meagher, Andrea Minervini, Maria C. Mir, Clara Cerrato, Giacomo Rebez, Riccardo Autorino, Lance Hampton, Riccardo Campi, Maximilian Kriegmair, Estefania Linares, Vital Hevia, Maria Musquera, Mauricio D'Anna, Eduard Roussel, Maarten Albersen, Nicola Pavan, Francesco Claps, Alessandro Antonelli, Michele Marchioni, Nail Paksoy, Selcuk Erdem, Ithaar H. Derweesh
Publikováno v:
European Urology Open Science, Vol 63, Iss , Pp 71-80 (2024)
Background and objective: The role of cytoreductive nephrectomy (CN) in the treatment of metastatic renal cell carcinoma (mRCC) has been called into question on the basis of clinical trial data from the tyrosine kinase inhibitor (TKI) era. Comparativ
Externí odkaz:
https://doaj.org/article/c9b891e3acc74122903fbba9bac3c4e0
Autor:
Laura Iisager, Johanne Ahrenfeldt, Frede Donskov, Börje Ljungberg, Axel Bex, Lars Lund, Iben Lyskjær, Niels Fristrup
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Primary tumor removal by cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma patients has been investigated in the context of various treatment regimens. Two randomized controlled trials investigated the role
Externí odkaz:
https://doaj.org/article/76866e452a284449961d4a715fa97939
Autor:
Piotr Domański, Jadwiga Jarosińska, Barbara Kruczyk, Mateusz Piętak, Anna Mydlak, Tomasz Demkow, Łukasz Kuncman, Marta Darewicz, Bożena Sikora-Kupis, Wojciech Michalski, Jakub Kucharz
Publikováno v:
Contemporary Oncology, Vol 27, Iss 4, Pp 242-248 (2024)
Externí odkaz:
https://doaj.org/article/ac324b6385744488a33d96c85b6e5c03
Publikováno v:
Clinical Case Reports, Vol 12, Iss 6, Pp n/a-n/a (2024)
Key Clinical Message Palliative surgical resection of extra‐calvarial metastatic lesions from renal cell tumors is crucial for controlling metastatic spread, improving quality of life, and preventing associated morbidity. Careful surgical planning,
Externí odkaz:
https://doaj.org/article/044c9e8a6cd04d2eb1b65f8bb7127a75
Autor:
Nargiz Majidova, Mustafa Seyyar, Demet Işık Bayraktar, Gülhan Dinç, Elfag İsgandarov, Javid Huseynov, Alper Yaşar, Abdussamet Çelebi, Nadiye Sever, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Rukiye Arıkan, Selver Işık, Özlem Ercelep, Güzin Demirağ, Umut Kefeli, Osman Köstek, İbrahim Vedat Bayoğlu, Murat Sarı
Publikováno v:
Biomolecules & Biomedicine (2024)
Many developing countries lack access to recommended first-line treatments for metastatic renal cell carcinoma (mRCC), such as immune checkpoint inhibitors (ICIs) or ICI-tyrosine kinase inhibitor (TKI) combinations. As a result, predictive markers ar
Externí odkaz:
https://doaj.org/article/6efa41f2967843798260bb7a256b080e